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1. Introduction
Cytokines and Rheumatoid Arthritis
The term “cytokine” is coined from the combination of “cyto”, a prefix which means cell,
and “kine”, which denotes movement.
Cytokines all have the following features:
1. They are low-molecular-weight glycoproteins that are not hormones.
2. They have an effect at very small concentrations.
3. Different cytokines can have the same function (redundancy).
For example, both tumor necrosis factor (TNF) and interleukin-6 (IL-6) have synovial prolif‐
eration activity and destroy articular cartilage and bone.
4. One cytokine can act on various organs at the same time (pleiotropy).
For example, TNF causes synovial proliferation, destroys articular cartilage, and promotes
fever.
5. Each cytokine has a specific receptor and acts by binding to that receptor.
Inflammatory cytokines play a central role in rheumatoid arthritis. In the treatment of rheu‐
matoid arthritis with biological agents, the effects of cytokines are suppressed by blocking
the cytokine from binding to its specific receptor (Figure 1).
With respect to these cytokines, antibodies and antibody fusion proteins that inhibit the ac‐
tion of IL-1, IL-6, and TNF have already been commercialized, and development of an IL-17
inhibitor is underway (Figure 2,Table 1).
© 2013 Matsuno; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Antibodies for the treatment of rheumatoid arthritis can be divided into three groups: chi‐
meric antibodies, humanized antibodies, and human antibodies. Experimental monoclonal
antibodies are usually produced by immunizing a mouse with an antigen, and therefore, the
antibody is 100% mouse antibody. When such an antibody is used as a therapeutic agent in
humans, it causes a strong anaphylactic reaction. In an effort to reduce as far as possible the
content of heterologous proteins, various chimeric antibodies, humanized antibodies, and
human antibodies have been developed for the treatment of rheumatoid arthritis.
Figure 1. Mechanisms of infliximab and tocilizumab
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Figure 2. Types of biological agents developed for the treatment of rheumatoid arthritis.
A chimeric antibody is produced first as a mouse monoclonal antibody by immunizing a
mouse with an antigen. Then the antigen binding site is preserved as it is, while the Fc site is
artificially replaced with one of human origin such as IgG1 or IgG4. In chimeric antibodies,
since about 25% mouse protein remains, anaphylactic reactions still occur about 10% of the
time when they are administered. There are also reports of treatment with antibody prepa‐
rations being impaired when antibodies to the chimeric antibody are produced.
A humanized antibody is produced first as a mouse monoclonal antibody, then only the
variable parts of the antigen binding site on the heavy chain and light chain of the antibody
are left as mouse protein, and the rest is replaced with human protein. Since protein which
codes the CDR1, CDR2, and CDR3 regions accounts for about 10% of the total, there is still a
small chance of anaphylactic reaction with multiple administrations, though less than that
with chimeric antibodies.
Human antibodies are fully human antibodies produced by the phage display method. A
typical example is adalimumab. This antibody is produced as follows: An antibody light
chain and antibody heavy chain, each with a strong affinity for TNF-α, are selected, and
then the two are bound together. Therefore, while it is a fully human protein, it is not an
antibody that is physiologically produced in humans. Consequently, it is reported that anti‐
bodies against the antibody are detected in 40% of cases or more, reducing the function of
the antibody preparation. Combined use of an immunosuppressant to prevent antibody
production is recommended.
Another fully humanized antibody on the market is golimumab. This antibody is produced
by a method different from that of adalimumab. First, a humanized transgenic mouse is pro‐
duced, the mouse is immunized with TNF, and the antibodies produced are purified and
commercialized. This method has made it possible to produce an antibody which is closer to
human than adalimumab.
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Target TNF-
Product name Remicade Enbrel Humira Simponi Cimzia
Non-proprietary
name Infliximab Etanercept Adalimumab Golimumab
Certolizumab
pegol
Indications
rheumatoid arthritis,
uveitis, Behcet’s
disease, plaque
psoriasis, pustular
psoriasis,
arthropathic
psoriasis,
erythrodermic
psoriasis, Crohn’s
disease, ulcerative
colitis
rheumatoid
arthritis, poly
juvenile
idiopathic
arthritis.
rheumatoid arthritis,
poly juvenile
idiopathic arthritis,
plaque psoriasis,
arthropathic
psoriasis, ankylosing
spondylitis, Crohn’s
disease
rheumatoid arthritis
rheumatoid
arthritis, Crohn’s
disease
Administration
method Drip infusion
Subcutaneous
injection
Subcutaneous
injection
Subcutaneous
injection
Subcutaneous
injection
Administration
interval
At wk 0, wk 2, wk 6,
then every 8 wks Every 1–2 wks Every 2 wks Every 4 wks Every 4 wks
Structure Chimeric antibody TNFR–IgG1 fusionprotein Human antibody Human antibody
Pegylated
humanized
antibody
Representative
clinical study ATTRACT
[1] ASPIRE[2] ERA[3] TEMPO[4] PREMIER
[5]
DE019[6]
GO-FORWARD[7] GO-
AFTER[8]
FAST4WARD[9]
RAPID2[10]
Target IL-1Rreceptor IL-6Receptor CD80/86 CD20
Product name Kineret Actemra(RoActemra) Orencia Rituxan (MabThera)
Non-proprietary
name Anakinra Tocilizumab Abatacept Rituximab
Indications rheumatoid arthritis
rheumatoid
arthritis, poly
juvenile idiopathic
arthritis, systemic
juvenile idiopathic
arthritis,
Castleman’s
disease
rheumatoid
arthritis
rheumatoid arthritis, non-Hodgkin’s
lymphoma
Administration
method
Subcutaneous
injection Drip infusion Drip infusion Drip infusion
Administration
interval Every 1 or 2 days Every 4 wks Every 4 wks Day 1 and 15, then every 24 wks
Structure IL-1 receptorantagonist
Humanized
antibody
CTLA-4–IgG1 fusion
protein Chimeric antibody
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recombinant
protein
Representative
clinical study
[11, 12] SAMURAI[13]
OPTION[14] AIM
[15] ATTAIN[16] REFLEX[17] SERENE[18]
Table 1. Characteristics of various biological agents
2. Types of Cytokine Inhibitors (Biological Agents) and their effects on
Rheumatoid Arthritis
Cytokine inhibitors used in the treatment of rheumatoid arthritis are inhibitors of IL-1 (ana‐
kinra), TNF (infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol), and
IL-6 (tocilizumab). In addition, biological agents other than cytokine inhibitors used in the
treatment of rheumatoid arthritis include abatacept, which inhibits the action of T-cell co-
stimulatory molecules CD80 and CD86, and rituximab, which targets CD20.
These drugs each have a stronger effect than methotrexate(MTX), which is considered to be
most effective taken orally, and each has strong action to suppress bone and joint destruc‐
tion (Figure 3, Figure. 4) [19].
Treatment with any biological agent is more effective than MTX monotherapy, and each
suppresses bone and joint destruction.
Figure 3. Improvement of clinical symptoms with biological agents
Figure 4. Suppression of joint destruction with biological agents
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3. Recommendations for the Use of Biological Agents
Opinion is divided on which biological agent should be used to start with when active rheu‐
matoid arthritis is diagnosed. Among typical rankings for the use of biological agents, there
is the 2012 recommendation of the American College of Rheumatology (Figure 5) [20].
According to this recommendation, in the United States the first biological agent (1st Bio)
recommended for treatment of early rheumatoid arthritis with disease duration of less than 6
months is a TNF inhibitor. For treatment of established RA with disease duration of 6 months
or more, a TNF inhibitor and abatacept or rituximab are recommended as the 1st Bio.
Figure 5. American College of Rheumatology 2012 Recommendation
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On the other hand, the British National Institute for Health and Clinical Excellence (NICE)
specifies the following guidance on usage (Figure 6) [21–27]:
Figure 6. *1The annual cost of the biological agent is also specified and does not exceed ₤9,295 a year.*2If certolizu‐
mab pegol is the 1st Bio, there should be a system wherein the manufacturer provides the first 12 weeks for free [23].
*3If golimumab is used as the 1st Bio, compensation from the manufacturer is necessary so that the drug price of 50
mg and 100 mg is the same [24].*4Tocilizumab can be used as the 1st Bio with a discount provided by the manufactur‐
er. Therefore, whichever biological agent is used first, the annual cost of any is ₤9,295 or less [27].NICE guidance on
the treatment of patients with rheumatoid arthritis.
4. Selecting Biological Agents by Efficacy and Safety
Among TNF inhibitors, there are several biological agents to choose from, with no strict
standards for which biological agent to use first in either the United States or the United
Kingdom. Most physicians choose one based on their own experience. Recently however,
data has begun to accumulate suggesting which usage is best.
Regarding efficacy, there is data indicating that etanercept is more effective than infliximab
for active rheumatoid arthritis with high levels of anti-cyclic citrullinated peptide antibod‐
ies  and rheumatoid factor [28].  In addition,  among infliximab,  adalimumab, and etaner‐
cept, it is reported that etanercept shows the highest efficacy in patients with high levels of
anti-SS-A antibody [29].
With respect to adverse reactions, the occurrence of tuberculosis among patients treated with
anti TNF agents has been shown to be low for the fusion protein preparation etanercept and
high for the antibody preparations infliximab and adalimumab. It has been suggested that the
reason for this could be that the antibody preparations, unlike the fusion protein prepara‐
tion etanercept, simultaneously suppress the function of macrophages [30, 31].
Therefore, from the point of view of adverse reactions, etanercept may be the best choice for
rheumatoid arthritis patients with a risk of tuberculosis.
The same could possibly be considered for tocilizumab, an IL-6 inhibitor which does not di‐
rectly suppress macrophage function. A postmarketing survey of tocilizumab as used in a
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real-world clinical setting has shown an incidence of tuberculosis of 0.22% [32], which is
lower than that of TNF inhibitors.
In comparative studies of related biological agents, almost no difference in efficacy was seen
between infliximab and abatacept [33] or between adalimumab and abatacept [34]. Howev‐
er, in a study comparing adalimumab and tocilizumab, tocilizumab was shown to be more
effective than adalimumab [35] (Table 2).
ATTEST Study AMPLE Study ADACTA Study
Agents Abatacept
vs.
Infliximab
Abatacept + MTX
vs.
Adalimumab + MTX
Tocilizumab
vs.
Abatacept
Primary endpoint DAS28(ESR) ACR20 DAS28(ESR)
Study period 1 year 1 year 24 weeks
Result −2.88 vs.−2.25 (n.s) 64.8% vs. 63.4% (n.s) −3.3 vs. −1.8 (p < 0.0001)
Table 2. Comparative study of related biological agents
Considered this way, the non-TNF cytokine inhibitor (IL-6 inhibitor) tocilizumab could be a
biological agent with greater pharmacological effect than TNF inhibitors with fewer adverse
reactions due to tuberculosis if used appropriately. Comparison of TNF and IL-6 shows
mostly the same pharmacological effects due to cytokine redundancy. Examples of this in‐
clude the induction of synovial proliferation, induction of inflammatory cytokines, and ar‐
ticular destruction.
Figure 7. Degree of DAS28 remission with tocilizumab treatment (own data)
Innovative Rheumatology102
However, a characteristic effect of IL-6, which is stronger than that of TNF, is the induction
of peripheral platelets in bone marrow megakaryocytes. The effect of IL-6 to induce C-reac‐
tive protein in hepatocytes is also thought to be stronger than the effect of TNF.
When the outcomes of cases in which tocilizumab was selected as the 1st Bio were com‐
pared in rheumatoid arthritis patients stratified by pre-treatment platelet levels, improve‐
ment in rheumatoid activity due to tocilizumab was found to be more marked in patients
with high pre-treatment platelet levels (≥400,000 /μL of blood) than in those with normal
platelet levels (Figure 7).
From these results, the effects of IL-6 are stronger than the effects of TNF in patients with
rheumatoid arthritis of high activity and high platelet levels, which might be a good indica‐
tion for the use of tocilizumab. In SCID-Hu-RA experimented mouse, which is implanted
human RA synovium into back of the severe combined immune deficient (SCID) mouse, hu‐
man RA synovium is markedly suppressed by tocilizumab treatment in compared with con‐
trol mouse [36].Tocilizumab not only improves clinical symptoms of rheumatoid arthritis,
but is also effective in improving pathological findings in rheumatoid arthritis (Figure 8).
Figure 8. Typical changes in synovial membrane seen with tocilizumab treatment
Inflammatory cells in synovial membrane are suppressed by tocilizumab and replaced by fi‐
brous tissue or adipose tissue.
5. Problems with Biological Agents
Biological agents are a very useful treatment for active rheumatoid arthritis, but there are
still many problems which must be solved, including their high cost and the problem of ad‐
verse reactions such as infections. As described in the US recommendation and UK guid‐
ance, they should probably be used in patients who do not obtain symptomatic relief
following treatment with DMARDs.
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